Endocrine Therapy Drugs (ETDs); Used to Treat Cancer That Use Hormones to Grow, Such as Breast and Prostate Cancer
Endocrine Therapy Drugs (ETDs) |
Endocrine Therapy Drugs
(ETDs) are used to add, block, or remove hormones
or chemicals to treat a variety of diseases such as breast cancer, diabetes,
and more. Endocrine therapy, also known as hormone therapy, is used to treat
cancer that use hormones to grow, such as prostate cancer and breast cancer. Endocrine
Therapy Drugs (ETDs) are
often used to treat cancer that slows or stops the growth of cancer that uses
hormones to grow. Treating cancer with hormones is called hormone therapy,
hormonal therapy, or endocrine therapy.
Among
the various treatment options for breast cancer, Endocrine Therapy (or hormone therapy) is one of the most effective
forms of targeted adjuvant therapy for hormone-responsive patients. It involves
removing or blocking the hormones (chemical messengers) that stimulate tumor
growth. The goal of treatment is to prevent recurrence. The current standard of
care is surgery, which is usually followed by chemotherapy or radiation
therapy. Increasing research has investigated the underlying mechanism of
endocrine resistance.
In
particular, several studies have been conducted on modulating apoptosis
machinery to overcome endocrine resistance. There are several different type of
hormone therapy drugs. Endocrine Therapy
Drugs (ETDs), such as aromatase inhibitors, selective estrogen receptor
modulators (SERMs), luteinizing hormone-releasing hormone (LHRH) agonists, and
estrogen receptor antagonists are used to treat breast cancer. While, CYP17
inhibitors, luteinizing hormone-releasing hormone (LHRH) agonists and
antagonists, and anti-androgens are used to treat prostate cancer.
In
October 2021, the United States Food and Drug Administration (USFDA) approved
abemaciclib with endocrine therapy for early breast cancer. Moreover, in August
2022, FDA approved Enhertu, an IV infusion for the treatment of patients with
unresectable (unable to be removed) or metastatic HER2-low breast cancer. This
is the first approved therapy targeted to patients with HER2-low breast cancer
subtype, which is a newly defined subset of HER2-negative breast cancer.
Comments
Post a Comment